NathanCharlesBahrMDMS-CR, FIDSA(He/Him)

HIV/AIDS Medicine, International Health, Travel & Tropical, Mycobacterial Disease

Associate Professor at the University of Minnesota

Dr. Bahr is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am an associate professor of Infectious disease at the University of Minnesota. My current research centers on improving diagnostics for TB meningitis and histoplasmosis as well as improving care, evaluating novel therapies and minimizing treatment toxicity for patients with Cryptococcal meningitis and TB meningitis.

University of Kansas School of MedicineFellowship, Infectious Disease, 2015 - 2016
University of MinnesotaFellowship, Infectious Disease, 2013 - 2015
National Institutes of Health - Fogarty International CenterFellow, Tuberculosis Meningitis, Cryptococcal Meningitis, 2013 - 2014
University of MinnesotaChief Residency, Internal Medicine, 2012 - 2013
University of MinnesotaResidency, Internal Medicine, 2009 - 2012
Loyola University Chicago Stritch School of MedicineClass of 2009

PubMed

2 citations
Antifungal drug price increases in the United States, 2000-2019.
Christine M Thomas, Whitney Shae, Devin Koestler, Terese DeFor, Nathan C Bahr
Mycoses. 2022-09-01
197 citations
Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.
Nathan C. Bahr, Edwin Nuwagira, Emily E Evans, Fiona V Cresswell, Philip V Bystrom
The Lancet. Infectious Diseases. 2018-01-01
132 citations
Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.
Joshua Rhein, Bozena M. Morawski, Katherine Huppler Hullsiek, Henry W. Nabeta, Reuben Kiggundu
The Lancet. Infectious Diseases. 2016-07-01

Kansas Health Experts Monitoring COVID-19, Flu and RSV Trifecta as Holiday Season ArrivesNovember 24th, 2022
If the New COVID Variant Is Resistant to Immunity, Are the Vaccines and Boosters Worth It?July 19th, 2022
Generic Hepatitis Drug Cost Savings Not Passed on to PatientsJune 26th, 2022
Join now to see all

Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitisNIAID2022–2027
Novel diagnostic development for TB meningitis and histoplasmosisNational Institutes of Neurologic Disorders and Stroke2019–2024